RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria-Reference-Cited by-同舟云学术

RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria

Published:2022-01-23 Issue:5 Volume:291 Page:593-610
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Sardh Eliane¹^ORCID,Harper Pauline²

Affiliation:

1. Department of Molecular Medicine and Surgery Centre for Inherited Metabolic Diseases Porphyria Centre Sweden Department of Endocrinology Karolinska Institutet Karolinska University Hospital Stockholm Sweden

2. Department of Medical Biochemistry and Biophysics Centre for inherited Metabolic Diseases, Porphyria Centre Sweden. Karolinska Institutet, Karolinska University Hospital Stockholm Sweden

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.13443

Reference101 articles.

1. Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes

2. Heme biosynthesis and the porphyrias

3. Biosynthesis of heme in mammals

4. Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias

5. Corrigendum to “Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias” [Med. Hypotheses 131 (2019) 109314]

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and tolerability of givosiran for the management of acute hepatic porphyria: A monocenter real-life evaluation;Molecular Genetics and Metabolism Reports;2024-09

2. Application of therapeutic nucleic acids and RNA interference to create products for personalised medicine;Biological Products. Prevention, Diagnosis, Treatment;2024-06-14

3. Exploring current and emerging therapies for porphyrias;Liver International;2024-05-30

4. The Growing Class of Novel RNAi Therapeutics;Molecular Pharmacology;2024-05-06

5. Hydroxymethylbilane Synthase Gene Mutation: The Hidden Driver of Abdominal Pain and Neurological Symptoms in Acute Intermittent Porphyria;Journal of Applied Hematology;2024-04